publication venue for
- Newer formulations of intravenous iron: a review of their chemistry and key safety aspects – hypersensitivity, hypophosphatemia, and cardiovascular safety. 20:757-769. 2021
- The reporting of observational studies of drug effectiveness and safety: recommendations to extend existing guidelines. 20:1-8. 2021
- The cardiovascular effect of incretin-based therapies among type 2 diabetes: a systematic review and network meta-analysis. 17:243-249. 2018
- Tiotropium for the treatment of asthma: a drug safety evaluation. 15:1115-1124. 2016
- Is it safe to use smoking cessation therapeutics during pregnancy?. 13:1721-1731. 2014
- Patient reports of the frequency and severity of adverse reactions associated with biological agents prescribed for psoriasis in Brazil. 13:1155-1163. 2014
- Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls. 13:25-43. 2014
- Safe use of long-acting β-agonists: what have we learnt?. 10:767-778. 2011
- Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes. 8:129-144. 2009
- The safety of fondaparinux for the prevention and treatment of venous thromboembolism. 4:707-721. 2005
- The safety of antidepressant use in pregnancy. 4:273-284. 2005
- The safety of antithrombotic therapy during pregnancy. 3:113-118. 2004
- Treatment of premenstrual dysphoria with selective serotonin re-uptake inhibitors: focus on safety. 2:161-166. 2003
- The gastrointestinal tolerability and safety of oral bisphosphonates. 1:71-78. 2002